ProCE Banner Series

PCE Cardiology Bootcamp

Join a panel of national expert faculty as they bring you the latest updates and clinical perspectives on management of cardiovascular conditions. Created specifically for the clinical needs of NPs and PAs who care for patients with cardiovascular diseases. Live streamed for your convenience – all from the comfort of your home or office.

  AAPA
  | ANCC
Credits Available

3.00
ANCC | AAPA

Who Should Attend

NPs and PAs who care for patients with cardiovascular diseases

All Events

PCE Cardiology Bootcamp

Past Events

December

11

2022

10:00 AM - 1:50 PM Eastern Time (ET)

Virtual

Topics

Current Challenges and Emerging Treatments for the Management of Resistant Hypertension

Optimizing Management of Patients With Cardiometabolic and Renal Disease: A Case-Based Multidisciplinary Discussion

APAC Educational Brief: Finerenone

APAC Educational Brief: CHF and the pillars of guideline directed therapy for HFpEF and HFrEF

Additional Info


CME/CE Info

Program Overview
Join a panel of national expert faculty as they bring you the latest updates and clinical perspectives on management of cardiovascular conditions. Created specifically for the clinical needs of NPs and PAs who care for patients with cardiovascular diseases. Live streamed for your convenience – all from the comfort of your home or office.


Target Audience
NPs and PAs who care for patients with cardiovascular diseases


Learning Objectives:

Current Challenges and Emerging Treatments for the Management of Resistant Hypertension

  • Identify barriers to achieving blood pressure goals in patients with resistant hypertension
  • Assess patients with uncontrolled blood pressure for resistant hypertension
  • Discuss the rationale for targeting the endothelin system to manage hypertension
  • Develop strategies to achieve blood pressure goals in patients with resistant hypertension based on the latest evidence, guideline recommendations, and patient-specific factors


Optimizing Management of Patients With Cardiometabolic and Renal Disease: A Case-Based Multidisciplinary Discussion

  • Evaluate the clinical evidence for SGLT2 inhibitors beyond glycemic control
  • Differentiate among the SGLT2 inhibitors when selecting therapy for individual patients with diabetes, HF, and CKD
  • Integrate SGLT2 inhibitors into treatment of appropriate patients according to evidence-based guidelines and patient-specific factors

Accreditation



Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Academy of Physician Associates in Cardiology (APAC). Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.0 contact hours.


AAPA Credit Designation

 Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



Disclosure of Conflicts of Interest 
Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with the Academy of Physician Associates in Cardiology (APAC)

Supported by educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC and Boehringer Ingelheim Pharmaceuticals, Inc.